FIT Biotech | Date: 2014-01-13
A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.
FIT Biotech | Date: 2016-05-02
Pharmaceutical preparations and vaccines against infectious diseases, especially against HIV; preparations used in gene therapy and vectors for gene therapy.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-2.3.2-4 | Award Amount: 15.44M | Year: 2010
Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUTHIVAC consortium gathers knowledges and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUTHIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUTHIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.
Saarikettu J.,University of Tampere |
Ovod V.,FIT Biotech |
Vuoksio M.,University of Tampere |
Gronholm J.,University of Tampere |
And 3 more authors.
Hybridoma | Year: 2010
Tudor-SN is a multifunctional regulator of gene expression that has been shown to function as a transcriptional co-activator, regulator of miRNA processing, mRNA splicing, and stability. Tudor-SN has also been identified as a component in RNA-induced silencing complex. Here we have produced and characterized seven monoclonal antibody (MAb) clones against human Tudor-SN. Antibodies were generated against the fourth staphylococcal nuclease-like domain (SN4) and the Tudor domain of human Tudor-SN. The MAbs recognize the Tudor-SN protein in Western blot analysis and immunoprecipitation, and detect the specific antigen in immunohistochemistry assays. One of the antibody clones also recognizes the Drosophila melanogaster and Danio rerio Tudor-SN. Immunocytochemistry of HeLa cells revealed Tudor-SN localization in nucleolus, suggesting a possible new function for the protein in the compartment. An extensive expression analysis in human tissue arrays shows moderate to high expression of Tudor-SN in a wide range of organs and tissues, especially in epithelial cell types. © Copyright 2010, Mary Ann Liebert, Inc.
FIT Biotech | Entity website
Key figures 1,000euro Jan 1Dec 31/2015 Jan 1Dec 31/2014 July 131 Dec/2015 July 1 31 Dec/2014 Revenue 20,00 30,00 0,00 20,00 Operating profit/loss 3 842,90 -2 290,70 -1 544,90 -1 197,30 Adjusted operating profit/loss (* -2 642,30 -2 290,70 -1 544,90 -1 197,30 Profit for the period 2 615,60 -2 304,10 -1 544,77 -1 210,38 Adjusted profit for the period(** -2 628,60 -2 304,10 -1 544,70 -1 210,38 Cash flow from operations -2 432,30 -1 203,70 Liquid assets 1 844,80 217,30 1 844,80 217,30 Equity -9 274,70 -21 348,60 -9 274,70 -21 348,60 Grants 6 539,20 205,00 0,00 180,00 Balance sheet total 2 693,70 1 020,90 2 693,70 1 020,90 (* adjusted for the EUR 6,485,213.20 subordinated loan not collected by Tekes (** excluding the financial advisers fees